Showing results 1 to 1 of 1
Issue Date | Title | Journal Title |
---|---|---|
2022 | Patient-reported outcomes (PROs) from DESTINY-Breast04, a randomized phase III study of trastuzumab deruxtecan (T-DXd) vs treatment of physician's choice (TPC) in patients (pts) with HER2-low metastatic breast cancer (MBC) | ANNALS OF ONCOLOGY |